Summary
The global Pneumococcal Conjugate Vaccine (PCV) Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2020.
Pneumococcal conjugated vaccine prevents infection with bacteria called Streptococcus pneumoniae, the causative agent of respiratory tract infections in humans. This vaccine is recommended for every newborn in order to minimize the risks of perinatal infection and to ensure the newborn is protected from infection in the first weeks of life. The main benefits of this vaccine include preventing severe complications of pneumococcal meningitis, prevention of complications of non-bronchial infection and protection of the newborn from death caused by bacteria.
Conjugate pneumococcal vaccines are used to prevent disease caused by a bacterium called Streptococcus pneumoniae, which is responsible for about 25% of all hospital admissions in the United States each year.
Market Dynamics
Increasing government initiatives in creating awareness is expected to propel growth of the pneumococcal conjugate vaccines market over the forecast period. For instance, in November 2019, the Union Ministry for Health and Family Welfare, India, launched the campaign SAANS (Social Awareness and Action to Neutralize Pneumonia Successfully) in order to fight child mortality due to pneumococcal contamination.
Asia Pacific is expected to witness significant growth in the pneumococcal conjugate vaccines market, owing to high burden of pneumonia in India, Pakistan, and Bangladesh. For instance, in India, pneumonia became the biggest killer infection in 2018, according to the National Health Profile, India, leading to 127,000 deaths of children under the age of five.
Major players operating in the pneumococcal conjugate vaccines market are focused on R&D of vaccines to enhance their market share. For instance, in March 2020, Pfizer announced its Phase 3 results of study of 20-Valent Pneumococcal Conjugate Vaccine stating that it had met their immunogenicity objective.
Key Takeaways
- Increasing government initiatives in creating awareness is expected to propel growth of the pneumococcal conjugate vaccines market over the forecast period
- Major players operating in the pneumococcal conjugate vaccines market are focused on R&D of vaccines for people 50 years of age or older and people two years and younger who are at increased risk for pneumococcal disease. For instance, in October 2020, Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine. The two trials are PNEU-PATH and PNEU-DAY. PNEU-PATH evaluated V114 after administration of PNEUMOVAX 23 on year later in healthy adults 50 years of age or older.
- Major players operating in the pneumococcal conjugate vaccines market include, Pfizer, Inc., GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic, and Serum Institute of India
The Pneumococcal Conjugate Vaccine (PCV) Market report highlights product development and growth strategies such as mergers and acquisitions adopted by market players along with SWOT Analysis, PEST, and Porter’s Five Forces analyses of the Pneumococcal Conjugate Vaccine (PCV) Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Pfizer
- GSK
- Sanofi
- Merck
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Zhifei Biologic
- Serum Institute of India
By Product Type, the market is primarily segmented into:
- 23-valent Vaccine
- 10-valent Vaccine
- 7-valent Vaccine
- 13-valent Vaccine
By Applications, the market is segmented into:
The report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
The objective of the Pneumococcal Conjugate Vaccine (PCV) Market Report:
- To assess the size of the market by value and volume
- Analyze the Pneumococcal Conjugate Vaccine (PCV) Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Pneumococcal Conjugate Vaccine (PCV) Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state-of-the-art tools and the current primary and secondary research approaches
- Discuss major factors that impact the growth of the Pneumococcal Conjugate Vaccine (PCV) Market
The Pneumococcal Conjugate Vaccine (PCV) Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Pneumococcal Conjugate Vaccine (PCV) Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type, and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into a specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Pneumococcal Conjugate Vaccine (PCV) Market Revenue
1.4 Market Analysis by Type
1.5 Market by Application
1.5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Application: 2020 VS 2026
1.6 Coronavirus Disease 2019 (Covid-19) Impact: Pneumococcal Conjugate Vaccine (PCV) Market
1.6.1 How the Covid-19 is Affecting the Pneumococcal Conjugate Vaccine (PCV) Market
1.6.1.1 Pneumococcal Conjugate Vaccine (PCV) Market Business Impact Assessment - Covid-19
1.6.2 Market Trends and Pneumococcal Conjugate Vaccine (PCV) Market Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Pneumococcal Conjugate Vaccine (PCV) Market Perspective (2015-2026)
2.2 Pneumococcal Conjugate Vaccine (PCV) Market Growth Trends by Regions
2.2.1 Pneumococcal Conjugate Vaccine (PCV) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Pneumococcal Conjugate Vaccine (PCV) Market Historic Market Share by Regions (2015-2020)
2.2.3 Pneumococcal Conjugate Vaccine (PCV) Market Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Pneumococcal Conjugate Vaccine (PCV) Market Growth Strategy
2.3.6 Primary Interviews with Key Pneumococcal Conjugate Vaccine (PCV) Market Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Market Players by Market Size
3.1.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Market Players by Revenue (2015-2020)
3.1.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Revenue Market Share by Players (2015-2020)
3.1.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Concentration Ratio
3.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Pneumococcal Conjugate Vaccine (PCV) Market Revenue in 2019
3.3 Pneumococcal Conjugate Vaccine (PCV) Market Key Players Head office and Area Served
3.4 Key Players Pneumococcal Conjugate Vaccine (PCV) Market Product Solution and Service
3.5 Date of entering into Pneumococcal Conjugate Vaccine (PCV) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Historic Market Size by Type (2015-2020)
4.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Forecasted Market Size by Type (2021-2026)
5 Pneumococcal Conjugate Vaccine (PCV) Market Breakdown Data by Application (2015-2026)
5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
5.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
6.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in North America (2019-2020)
6.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
6.4 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
7.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in Europe (2019-2020)
7.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
7.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
8 China
8.1 China Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
8.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in China (2019-2020)
8.3 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
8.4 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
9.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in Japan (2019-2020)
9.3 Japan Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
9.4 Japan Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
10.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
10.4 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
11 India
11.1 India Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
11.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in India (2019-2020)
11.3 India Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
11.4 India Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size (2015-2020)
12.2 Pneumococcal Conjugate Vaccine (PCV) Market Key Players in Central & South America (2019-2020)
12.3 Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020)
12.4 Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Company Details
13.2 Business Overview and Its Total Revenue
13.3 Pneumococcal Conjugate Vaccine (PCV) Market Introduction
13.4 Pneumococcal Conjugate Vaccine (PCV) Market Business (2015-2020)
13.5 Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Table
Table 1. Pneumococcal Conjugate Vaccine (PCV) Market Key Market Segments
Table 2. Key Players Covered: Ranking by Pneumococcal Conjugate Vaccine (PCV) Market Revenue
Table 3. Ranking of Global Top Pneumococcal Conjugate Vaccine (PCV) Market Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. COVID-19 Impact Global Market
Table 6. Opportunities and Trends for Pneumococcal Conjugate Vaccine (PCV) Market Players in the COVID-19 Landscape
Table 7. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 8. Key Regions/Countries Measures against Covid-19 Impact
Table 9. Proposal for Pneumococcal Conjugate Vaccine (PCV) Market Players to Combat Covid-19 Impact
Table 10. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Regions (2015-2020)
Table 14. Global Pneumococcal Conjugate Vaccine (PCV) Market Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Pneumococcal Conjugate Vaccine (PCV) Market Growth Strategy
Table 20. Main Points Interviewed from Key Pneumococcal Conjugate Vaccine (PCV) Market Players
Table 21. Global Pneumococcal Conjugate Vaccine (PCV) Market Revenue by Players (2015-2020) (Million US$)
Table 22. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Players (2015-2020)
Table 23. Global Top Pneumococcal Conjugate Vaccine (PCV) Market Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pneumococcal Conjugate Vaccine (PCV) Market as of 2019)
Table 24. Global Pneumococcal Conjugate Vaccine (PCV) Market by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Pneumococcal Conjugate Vaccine (PCV) Market Product Solution and Service
Table 27. Date of entering into Pneumococcal Conjugate Vaccine (PCV) Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 30. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2015-2020)
Table 31. Global Pneumococcal Conjugate Vaccine (PCV) Market Revenue Market Share by Type (2021-2026)
Table 31. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2015-2020)
Table 33. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 34. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2026)
Table 35. North America Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 37. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 38. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 39. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 40. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 41. Europe Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 43. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 45. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 47. China Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 48. China Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 49. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 50. China Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 51. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 52. China Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 53. Japan Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 55. Japan Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 57. Japan Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 61. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 63. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 65. India Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 66. India Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 67. India Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 68. India Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 69. India Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 70. India Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Pneumococcal Conjugate Vaccine (PCV) Market Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Pneumococcal Conjugate Vaccine (PCV) Market Share (2019-2020)
Table 73. Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2015-2020)
Table 75. Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2015-2020)
Table 77. Company Details
Table 78. Business Overview
Table 79. Product details
Table 80. Revenue in Pneumococcal Conjugate Vaccine (PCV) Market Business (2015-2020) (Million US$)
Table 81. Recent Development
List of Figures
Figure 1. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Type: 2020 VS 2026
Figure 2. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Application: 2020 VS 2026
Figure 3. Emergency Care Case Studies
Figure 4. Outpatient Facilities Case Studies
Figure 5. Hospitals Case Studies
Figure 6. Home Healthcare Facilities Case Studies
Figure 7. Pneumococcal Conjugate Vaccine (PCV) Market Report Years Considered
Figure 8. Global Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Regions: 2020 VS 2026
Figure 10. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Players in 2019
Figure 13. Global Top Pneumococcal Conjugate Vaccine (PCV) Market Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pneumococcal Conjugate Vaccine (PCV) Market as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Pneumococcal Conjugate Vaccine (PCV) Market Revenue in 2019
Figure 15. North America Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Pneumococcal Conjugate Vaccine (PCV) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Bottom-up and Top-down Approaches for This Report
Figure 23. Data Triangulation
Figure 24. Key Executives Interviewed
Request Discount 
Inquire Before Buy
